These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Toxicity and kinetics of amitraz in dogs. Author: Hugnet C, Buronrosse F, Pineau X, Cadoré JL, Lorgue G, Berny PJ. Journal: Am J Vet Res; 1996 Oct; 57(10):1506-10. PubMed ID: 8896693. Abstract: OBJECTIVE: To evaluate the toxic effects of amitraz in dogs and their reversal by various doses of atipamezole. ANIMALS: 6 male 1-year-old Beagles. PROCEDURE: Dogs were given 100 mg of amitraz/kg of body weight, PO. Atipamezole was administered at 3 dose rates. Clinical examination and blood sample collection were performed regularly for 48 hours to examine biological parameters and determine the toxicokinetics of amitraz as well as the efficacy of the antidote. A specific high-performance thin layer chromatographic method was developed to determine plasma amitraz concentrations. RESULTS: Clinical signs of toxicosis included sedation, bradycardia, polyuria, hypothermia, and hyperglycemia, all of which could be related to the alpha 2-agonist activity of amitraz, and were reversed by low doses of atipamezole (50 micrograms/kg, IM), a potent alpha 2-antagonist, within 10 minutes after injection. Peak plasma concentrations were observed after 5 hours, and the elimination half-life was long (about 24 hours). CONCLUSIONS: All clinical and biological effects observed during the course of amitraz poisoning could be attributed to the parent compound itself and were reversed by low doses of atipamezole. The half-life of amitraz was substantially longer than that in other studies because of the high dose administered. CLINICAL RELEVANCE: Atipamezole can be administered i.m. to dogs with severe amitraz poisoning to reverse all the effects observed.[Abstract] [Full Text] [Related] [New Search]